Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 32Terminated 7Unknown 6Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 4Burkitt Lymphoma 3Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Biphenotypic, Acute 2Thymoma 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatectomy 1Hematologic Neoplasms 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 28fludarabine 19Rituximab 17obinutuzumab 12venetoclax 10Lenalidomide 9Bendamustine Hydrochloride 9Prednisone 7zanubrutinib 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5ibrutinib 5fludarabine phosphate 5Biopsy 5glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × Methylprednisolone × Clear all
NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Recruiting
41 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡